Matinas biopharma holdings reports q3 loss per share of $0.03

Matinas biopharma reports third quarter 2019 financial results and provides corporate update.q3 loss per share $0.03.q3 earnings per share estimate $-0.03 -- refinitiv ibes data.cash and cash equivalents at september 30, 2019 were approximately $32.7 million.initiated pre-screening of patients for phase 2 enhance-it study of mat9001 against vascepa.believes that cash on hand is sufficient to fund operations into q1 of 2021.phase 2 enhance-it study of mat9001 enrollment to commence q1 2020, with topline data expected h2 2020.
MTNB Ratings Summary
MTNB Quant Ranking